IMVT
Immunovant, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Immunovant, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
No other changes.
No other changes.
Annual filing, covered
10-K parsed · May 20 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · May 20 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
+1.17%
vs ±9.0% implied · ×0.13
shaded = implied · ▲▼ = realized
Immunovant, Inc.
28.41
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $623.7M | 14.39% | −4.49% |
| Deep Track Capital | $359.9M | 8.31% | −18.96% |
| BlackRockindex-like | $276.7M | 6.38% | +9.22% |
| Farallon | $223.7M | 5.16% | +275.49% |
| Baker Bros. | $209.4M | 4.83% | −0.42% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $623.7M | 14.39% | −4.49% |
| Deep Track Capital | $359.9M | 8.31% | −18.96% |
| BlackRockindex-like | $276.7M | 6.38% | +9.22% |
| Farallon | $223.7M | 5.16% | +275.49% |
| Baker Bros. | $209.4M | 4.83% | −0.42% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Immunovant, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Immunovant, Inc.'s 6 closest co-movers, none share that code.
Bull2
Bear2
Linked news
Tall tick = annual report · Source: EDGAR
—
Expected move
Inputsspot 28.41exp Nov 20ATM strike 28ATM straddle 4.07IV 81%